Brookline, MA, United States of America

Daniel R McMasters


Average Co-Inventor Count = 21.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Brookline, MA (US) (2018 - 2019)
  • Boston, MA (US) (2019)

Company Filing History:


Years Active: 2018-2019

where 'Filed Patents' based on already Granted Patents

3 patents (USPTO):

Title: The Innovative Contributions of Daniel R. McMasters in Cancer Research

Introduction: Daniel R. McMasters is a notable inventor based in Brookline, MA, recognized for his significant advancements in the field of cancer treatment. With a total of three patents, his work primarily focuses on the development of tricyclic compounds that target mutant IDH enzymes, presenting promising prospects for cancer therapies.

Latest Patents: Among his latest innovations, Daniel's patents include formulations of tricyclic compounds, which serve as inhibitors of mutant IDH enzymes. These compounds are described by a specific chemical formula, aimed at offering potential treatment or prevention strategies for cancers associated with these enzymes. Moreover, his patents detail the compositions of these compounds and their therapeutic uses, further contributing to the fight against cancer by targeting the underlying enzymatic mechanisms involved.

Career Highlights: Daniel McMasters is part of Merck Sharp & Dohme Corporation, a leading pharmaceutical company committed to discovering and developing advanced healthcare solutions. His role in this innovative company highlights his commitment to the research and development of novel treatments, particularly in the oncology sector.

Collaborations: In his quest for innovation, Daniel collaborates with esteemed colleagues, such as Christian Fischer and Stephane L. Bogen. These partnerships foster a rich environment for brainstorming and developing groundbreaking ideas, enhancing the potential impact of their collective research efforts in the medical field.

Conclusion: Daniel R. McMasters exemplifies the spirit of innovation within cancer research through his groundbreaking patents and collaborations. His work on tricyclic compounds as inhibitors of mutant IDH enzymes not only showcases his inventive prowess but also promises significant advancements in cancer treatment strategies. The commitment to addressing complex medical challenges continues to define his career and impact in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…